Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
Objectives Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective.Design A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab pl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/12/e031019.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|